VeroVaccines GmbH. (2/25/25). "Press Release: VeroVaccines Secures a 7-digit Financing to Expand Its Vaccine Pipeline". Lüneburg.

	Organisation	VeroVaccines GmbH
	Organisation 2	EXISTING INVESTOR/S
	Group	OTHER
	Product	Unified Vaccine Platform (VeroVaccines)
	Product 2	venture capital
	Index term	VeroVaccines–SEVERAL: investment, 202502 financing round Series €1.6m from existing investors + founders
	Person	Hennemann, Hanjo (VeroVaccines GmbH 201707– Managing Direcotor + Co-Founder before Nexigen GmbH)
	Person 2	Behrens, Sven-Erik (Univ Halle 201805 Professor + VeroVaccines GmbH 201805 Managing Director + Co-Founder)

> Vaccine specialist secures financing of 1.6 million euros

> Almost all existing investors are participating in the round

> The funds will be used to expand the product pipeline

The veterinary vaccine developer VEROVACCiNES announces the successful completion of a €1.6 million financing round. The round was largely supported by existing investors as well as the founders. This underlines the joint confidence in the innovative strength and strategic direction of the company.

Following the rapid development of a highly efficacious vaccine against bluetongue virus type 3, VEROVACCiNES plans to use the funds raised specifically for the further expansion of its own product pipeline. The company will use its proprietary vaccine technology (Unified Vaccine Platform), which provides ONE coherent system for the generation, development, and production of innovative subunit vaccines along the entire value chain.

“The massive progress we have made over the past year in expanding our technology platform enables us to push ahead with the development of vaccines for our own pipeline and to launch further collaborations,” says Dr. Hanjo Hennemann, CEO of VEROVACCiNES. ”We are grateful to our investors for their support, which allows us to realize our ambitious development goals.”

The CSO of VEROVACCiNES, Prof. Sven-Erik Behrens, emphasizes the importance of the financing round: “With these funds, we can significantly accelerate our vaccine development and bring promising vaccine candidates to the next stage. Our goal is to bring innovative and efficacious vaccines to the market to meet the increasing challenges in animal health long term.”

The investor consortium, consisting of renowned investors from various European countries, is counting on VEROVACCiNES' potential to further revolutionize biotechnological vaccine development and to efficiently develop innovative products with high unique selling points.

About VEROVACCiNES:

VEROVACCiNES is an innovative biotechnology company specializing in the development of novel vaccines. The company's proprietary technology platform enables the rapid, cost-effective production of safe and effective vaccines for the veterinary sector. Thanks to intensive research and close collaboration with partners, the company is developing an attractive product pipeline to combat relevant animal diseases.

Contact:

VEROVACCiNES GmbH
Mareike Schünemann
Bluecherstrasse 26
06120 Halle (Saale), Germany
https://verovaccines.com/

Record changed: 2025-03-08